Mehlhorn H, Dankert W, Hartman PG, Then RL. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
Parasitol Res 1995;
81:296-301. [PMID:
7624286 DOI:
10.1007/bf00931533]
[Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The new bacteriocidal drug epiroprim (Ro-11-8958) was tested (alone or in combination with dapsone) on its efficacy against Toxoplasma gondii and Pneumocystis carinii in their hosts: laboratory mice and/or nude mice/rats, and was compared to the curative effects of the recent drugs of choice. The experiments clearly pointed out that epiroprim has significant effects on the reduction of both parasites when given alone. In combination with dapsone epiroprim led to a complete cure of toxoplasmosis in mice. This finding is of some importance for AIDS patients mostly suffering from bacteriosis and parasitosis at the same time.
Collapse